Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-HTK03170 in PSMA-positive mCRPC
NCT05570994Phase 2Enrolling by invitation
- Sponsor
- BC Cancer
- Start
- Jan 2024
- Primary completion
- Dec 2026
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
A Phase 2 trial of lutetium Lu-177 HTK03170 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by BC Cancer. Started Jan 2024; status: enrolling by invitation.
02
Drugs
lutetium Lu-177 HTK03170
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05570994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05570994.